InflaRx N.V. (IFRX) vs Lineage Cell Therapeutics (LCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 13.0% versus a loss of 45.2%. Over five years, IFRX leads with a -36.8% price change compared with -59.7% for LCTX. Lineage Cell Therapeutics is the larger company by market cap ($243.6 million vs $219.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | LCTX |
|---|---|---|
| Share price | $1.49 | $0.9633 |
| Market cap | $219.58M | $243.63M |
| 1-day change | -4.49% | +1.66% |
| YTD return | +54.46% | -43.26% |
| 1-year return | +13.04% | -45.23% |
| 5-year return | -36.84% | -59.68% |
| EPS (TTM) | $-0.58 | $-0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $2.09 |
| 52-week low | $0.798 | $0.88 |
| Distance from 52-week high | -49.47% | -53.91% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +414.09% | +470.95% |
| Average volume | 794.10K | 1.15M |
| Shares outstanding | 147.37M | 252.91M |
| Employees | 65 | 72 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed LCTX by 58.3 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
IFRX vs LCTX FAQ
Which is bigger, InflaRx N.V. or Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $243.63M compared with $219.58M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or LCTX?
IFRX returned +13.04% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Lineage Cell Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for InflaRx N.V. and Biotechnology: Biological Products (No Diagnostic Substances) for Lineage Cell Therapeutics.